“This year, there is no need for immediate cash infusion in Apollo HealthCo. It is being supported by Rs 130 crore of EBITDA coming from the backend pharmacy. So, there is cash for growth existing within the company and at the right valuation, we will look at a 10% dilution.”
| Subscribe To Our Free Newsletter |
